ESLA

Business Context and Reporting Period

Estrella Immunopharma, Inc. (ESLA), an emerging growth company, filed this Form 8-K on January 5, 2026, reporting the entry into a material definitive agreement. The company is headquartered in Emeryville, California, and its common stock and warrants trade on The Nasdaq Stock Market LLC.

Key Financial Metrics and Transaction Details

The filing details a capital raise consummated on January 6, 2026, consisting of a Registered Direct Offering and a concurrent Private Placement (PIPE). Key metrics include:

• Gross Proceeds: Approximately $8.0 million.
• Securities Issued:
  • 4,063,290 shares of Common Stock.
  • 1,000,000 Pre-Funded Warrants (exercisable at $0.00001 per share).
  • 7,594,935 PIPE Common Warrants (exercisable at $1.39 per share).
• Pricing:
  • Common Units (1 share + 1.5 PIPE Warrants): $1.58 per unit.
  • Pre-Funded Units (1 Pre-Funded Warrant + 1.5 PIPE Warrants): $1.57999 per unit.
• Placement Agent Fees: 6.0% of aggregate gross proceeds paid to Aegis Capital Corp.

The filing does not provide specific data on revenue, profit, cash flow, margins, or existing debt levels, as this is a current report regarding a specific transaction rather than a periodic financial statement.

Material Changes and Transaction Structure

The primary material change is the increase in outstanding equity and warrant obligations resulting from the Offerings. The transaction structure includes:

• Warrant Terms: PIPE Common Warrants expire on the fifth anniversary of issuance. Both Pre-Funded and PIPE Warrants contain ownership limitations preventing exercise if the holder would beneficially own more than 4.99% (or 9.99% upon election) of outstanding Common Stock.
• Exercise Mechanics: PIPE Common Warrants may be exercised on a cashless basis if no effective registration statement is available for the underlying shares.
• Registration Rights: The company agreed to file a resale registration statement within 30 days of closing and maintain its effectiveness until all securities are sold or eligible for resale under Rule 144.

Outlook, Management Commentary, and Risks

Use of Proceeds: Management intends to use the net proceeds for general corporate purposes and working capital.

Risks and Contingencies:

• Dilution: The issuance of shares and warrants will result in dilution to existing shareholders.
• Ownership Caps: The 4.99% ownership limitation may restrict the Investor's ability to exercise warrants fully without prior consent or election.
• Regulatory Timing: The effectiveness of the resale registration statement is subject to SEC review timelines (60 to 90 days).

Investor Verification Checklist

• Verify the exact net proceeds after deducting the 6.0% placement agent fee and other offering expenses.
• Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific anti-dilution adjustment formulas.
• Confirm the current number of outstanding shares to calculate the immediate dilution impact of the 4,063,290 new shares and potential warrant exercises.
• Monitor the filing status of the Resale Registration Statement to ensure it becomes effective within the agreed 60-day window.
• Check subsequent filings for any updates on the company's cash position and runway following the capital raise.